D-0041-2024 Class II Ongoing

Recalled by Eugia US LLC — East Windsor, NJ

FDA drug recall D-0041-2024 was initiated by Eugia US LLC on Sep 28, 2023 and is designated Class II. Reason for recall: Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial. The recall status is ongoing. Affected quantity: 1,626 vials.

Recall details

Product Type
Drugs
Report Date
Oct 11, 2023
Initiation Date
Sep 28, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,626 vials

Product description

Triamcinolone Acetonide Injectable Suspension, USP, 400 mg per 10 mL (40mg/mL), 10 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intra-articular use only, Shake Well, Not for IV/ID, intraocular, epidural, or intrathecal use, Mfd. in India for Auromedics Pharma LLC., E Windsor, NJ, 08520, NDC 55150-385-01.

Reason for recall

Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial.

Distribution pattern

Nationwide in the USA

Code information

Lot #: 3TC22010, Exp 11/30/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0041-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0041-2024. Report a data issue: hello@regdatalab.com.